Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
Eur J Clin Invest
; 47(2): 158-166, 2017 Feb.
Article
de En
| MEDLINE
| ID: mdl-28036121
ABSTRACT
BACKGROUND:
One of the risk factor to develop progressive multifocal leukoencephalopathy (PML) among natalizumab-treated patients is the presence and high levels of anti-JCV antibodies. Our purpose was to test the association of different clinical and demographic variables with the presence and levels of anti-JCV antibodies in a Spanish cohort of patients with multiple sclerosis (MS) during natalizumab treatment. MATERIALS ANDMETHODS:
All patients with MS from two hospitals with at least one measure of the anti-JCV antibodies levels (2011-2014) were recruited, among them were two PML cases. Anti-JCV antibody levels were assessed using two-step ELISA.RESULTS:
A total of 1061 patients (16·3% natalizumab-treated) participated in this study. The seropositivity rate of anti-JCV antibodies was 58·2%. It increased with age (Pcorrected = 0·00005) and was lower among HLA-DRB1*1501 carriers (Pcorrected = 0·049). The two patients with PML were HLA-DRB1*1501 carriers. We had at least three quarterly anti-JCV antibody measurements (index value) from 137 patients, whose levels did not increase during natalizumab treatment. However, 5·8% of these patients had an increase of the index value higher of one point in a maximum of 6 months, something that was more frequently observed (P = 0·054) among patients treated with immunosuppressant prior to natalizumab onset.CONCLUSIONS:
Old age and HLA-DRB1*1501 were the factors that influence positively and negatively, respectively, our anti-JCV antibody prevalence, although our both PML cases were HLA-DRB1*1501carriers. Most of our patients showed a stable anti-JCV antibody index values during natalizumab treatment.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Leucoencéphalopathie multifocale progressive
/
Virus JC
/
Natalizumab
/
Facteurs immunologiques
/
Anticorps antiviraux
/
Sclérose en plaques
Type d'étude:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limites:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Pays/Région comme sujet:
Europa
Langue:
En
Journal:
Eur J Clin Invest
Année:
2017
Type de document:
Article
Pays d'affiliation:
Espagne